MWNA
RPTX

Marshall Wace North America’s Repare Therapeutics RPTX Stock Holding History

Marshall Wace North America’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,087
Closed -$902K – 1438
2020
Q2 		$902K Buy
+29,087
New +$934K 0.01% 785

Other funds holding RPTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Marshall Wace North America's RPTX Position: Q3 2020 in Review

Marshall Wace North America sold out of Repare Therapeutics (RPTX) in Q3 2020, closing a stake of 29,087 shares — an estimated $902K sold.

Marshall Wace North America first reported a position in RPTX in Q2 2020 and held it in 1 quarter. The position peaked at $902K in Q2 2020. 39 funds tracked by Wall St. Rank hold RPTX as of Q3 2020.

  • Marshall Wace North America reported no remaining Repare Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 29,087 Repare Therapeutics shares in Q3 2020, an estimated $902K.
  • Marshall Wace North America first reported a position in Repare Therapeutics in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Repare Therapeutics position peaked at $902K in Q2 2020.
  • 39 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.